NCT04701619Not yet recruiting
Immuno-inflammatory Profile and Response to Ischemic Stroke Reperfusion Therapies (IMMUNOSTROKE)
Immuno-inflammatory Profile and Response to Ischemic Stroke Reperfusion Therapies
Source: ClinicalTrials.gov · Last updated 20 Jan 2026
Brief summary (registry, in English)
IMMUNOSTROKE study aims to describe the immuno-inflammatory and thrombo-inflammatory profiles during the course of AIC management by reperfusion treatment and to monitor changes in these different parameters over time. Post-hoc analyses will make it possible to correlate the immuno-inflammatory and thrombo-inflammatory profiles and their evolution with the clinical outcome in terms of post-AIC functional and cognitive disability.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- First submitted
- 25 Nov 2020
- Start date
- 15 Sept 2026
- Primary completion date
- 15 Oct 2027
- Lead sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
- Diseases
- Stroke
- NCT number
- NCT04701619
What you commit to
- Study type: Interventional
- Planned participants: 300
- From 15 Sept 2026 to the primary completion date, 15 Oct 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Intracranial hemorrhage associated with AIC on initial imaging
- Immunosuppressive treatment or corticosteroid therapy at patient admission
- Known and diagnosed dementia pre-existing at the time of the AIC
Lab values
- Absolute or relative contraindication to the injection of gadolinium (history of true allergic reaction or intolerance to gadobutrol, renal failure with creatinine clearance \<15mL/min, pregnant or breastfeeding women)
Other
- Contraindication to performing a brain MRI (claustrophobia, pacemaker, or other implantable device contraindicating the performance of an MRI)
- Pre-existing neurological disability limiting neurological assessment at 3 months (mRS\>2 at admission)
- Patient treated by another institution and referred solely for mechanical thrombectomy
- Patient benefiting from legal protection measures
Who the study is looking for
- Patient over 18 years of age
- Presenting with an ACS for which reperfusion therapy is indicated according to European and North American recommendations (IV thrombolysis or mechanical thrombectomy or a combination of both)
- Having received informed information about the study and having signed a consent form to participate in the study (if this is not possible: information and consent from a trusted person or family member if present; emergency inclusion if absent)
- Affiliated with or beneficiary of a social security system
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.